secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001140361-25-025673
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals appoints Christopher Stevens as COO; Patel shifts to President, Head of R&D
--------------------------------------------------------------------------------

- Christopher Stevens, age 45, appointed COO effective July 7, 2025; previously EVP at Spark Therapeutics.
- Kinnari Patel transitions from COO, President, Head of R&D to President, Head of R&D.
- Stevens receives $525,000 base salary, 45% target bonus, $250,000 sign-on, and ~$2.5M equity grant.
- Equity vests over 3 years; additional $500K equity grant after one year.
- Severance provisions: 9 months base plus COBRA; 12 months on change-in-control termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125025673/0001140361-25-025673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125025673/ef20051920_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-025673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer